Back

The Association between Age and Clinical Outcomes in Patients with Subclinical Atrial Fibrillation Treated with Apixaban: Insights from the ARTESiA Trial

2 September 2024 (15:51 - 16:03)
Organised by: Logo
Congress Presentation Part of: Smaller trials, trial updates, and other studies on antiplatelet and antithrombotic therapies Clinical ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Associate Professor Marco Proietti

University of Milan, Milan (Italy)

4 More presentations in this session

Presentation thumbnail
Long-acting Factor XI Inhibition and Periprocedural Bleeding: A Secondary Analysis from AZALEA-TIMI 71
Doctor S. Patel (Boston, US)
Slides Video
Presentation thumbnail
Aspirin and hemocompatibility related adverse events after LVAD implantation in patients with diabetes mellitus, obesity and atrial fibrillation: the ARIES-HM3 randomized clinical trial
Doctor N. Uriel (New York, US)
Slides Video
Presentation thumbnail
Efficacy and safety of anticoagulation in patients with device-detected atrial fibrillation by indication for acetylsalicylic acid therapy
Professor R. Schnabel (Hamburg, DE)
Slides Video
Presentation thumbnail
Changes in Cognitive Function in Patients with Subclinical Atrial Fibrillation Treated with Apixaban or Aspirin: A Sub-Study from the ARTESiA Trial
Doctor L. Rivard (Montreal, CA)
Video

Access the full session

Session thumbnail
Smaller trials, trial updates, and other studies on antiplatelet and antithrombotic therapies
Video

The Event

Event poster

ESC Congress 2024

2 September 2024 15:51 CET
You may be interested in
thumbnail
Congress Session
Smaller trials, trial updates, and other studies on antiplatelet and antithrombotic therapies
thumbnail
Congress Presentation
Risk of stroke or systemic embolism according to baseline frequency and duration of subclinical atrial fibrillation: Insights from the ARTESiA trial
thumbnail
Congress Presentation
Incidence and predictors of major bleeding among patients receiving apixaban or aspirin for subclinical atrial fibrillation: insights from the ARTESiA sub-analysis

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources